ArticleInternational journal of experimental pathology2010
Genetic regulation of pristane-induced oil granuloma responses.
Article in International journal of experimental pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Identification and characterization of miRNAs in spleens of sheep subjected to repetitive vaccination.Scientific reports · 2023Article
- Mouse innate-like B-1 lymphocytes promote inhaled particle-induced in vitro granuloma formation and inflammation in conjunction with macrophages.Archives of toxicology · 2022Article
- Retinoic Acid Exerts Disease Stage-Dependent Effects on Pristane-Induced Lupus.Frontiers in immunology · 2020Article
- Regulation of Leukocyte Recruitment to the Spleen and Peritoneal Cavity during Pristane-Induced Inflammation.Journal of immunology research · 2017Article
- Immunopathogenesis of granulomas in chronic autoinflammatory diseases.Clinical & translational immunology · 2016Review
- Efficient role of IgH 3' regulatory region deficient B-cells in the development of oil granulomas.Oncotarget · 2016Article
- B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy.PloS one · 2016Article
- Differential development of oil granulomas induced by pristane injection in galectin-3 deficient mice.BMC immunology · 2015Article
- B cell-deficient mice display enhanced susceptibility to Paracoccidioides brasiliensis Infection.Mycopathologia · 2013Article
- RORγt modulates macrophage recruitment during a hydrocarbon oil-induced inflammation.PloS one · 2013Article
- Emerging trends in the formation and function of tuberculosis granulomas.Frontiers in immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Oil granuloma (OG) induced by intraperitoneal injection of pristane represents a non-infectious granuloma. Oil granuloma has been characterized, but the regulation of its formation still remains unknown. To address this, we injected pristane into various mice deficient for genes including, linker for activation of T cells (LAT), μMT, LTα, TNFα, IL-6. T cell deficient mice (LAT(-/-) ) responded to pristane by developing serosal granuloma and mesenteric granuloma (MG) as in wild type mice. The absence of B cells blocked serosal granuloma (SG) formation and diminished MG development in response to pristane. However, even when a comparable number of B cells were present in the mesentery, the absence of TNFα resulted in similar defects in OG formation after pristane treatment, demonstrating that both B cells and TNFα are very crucial for pristane-induced OG formation. Interestingly, IL-6(-/-) mice had intact MG formation; however, SG organization was impaired. These studies provide insight into granulomateous pathology induced by non-infectious substances for example, biomedical sutures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.